Butler James J, Dankert John F, Keller Laura E, Azam Mohammad T, Dahmen Jari, Kerkhoffs Gino M M J, Kennedy John G
Foot and Ankle Division, Department of Orthopaedic Surgery, NYU Langone Health, New York City, NY, USA.
Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.
Cartilage. 2024 Dec 9:19476035241304308. doi: 10.1177/19476035241304308.
The purpose of this study was to determine the M1/M2 macrophage ratio in concentrated bone marrow aspirate (cBMA) in patients undergoing surgical intervention augmented with cBMA for osteochondral lesions of the talus (OLTs).
Samples of peripheral blood (PB), bone marrow aspirate (BMA), and cBMA were collected during the procedure. The samples were analyzed by automated cell counting and multicolor fluorescence-activated cell sorting with specific antibodies recognizing monocytes (CD14+ CD16+) and the M1 (CD86+) and M2 (CD163+CD206+) populations within that monocyte population. Cytokine concentrations within the samples were evaluated with enzyme-linked immunosorbent assay (ELISA). The composition of cBMA was compared between 2 commercially available BMA concentration systems.
Thirty-eight patients with a mean age of 43.2 ± 10.1 years old undergoing a surgical procedure for the treatment of OLTs involving the use of cBMA were included. cBMA had a mean fold increase of 4.7 for all white blood cells, 6.1 for monocytes, 7.9 for lymphocytes, 2.4 for neutrophils, and 9.6 for platelets when compared to BMA. The mean M1/M2 ratio for PB, BMA, and cBMA was 15.2 ± 12.0, 20.8 ± 13.3, and 22.1 ± 16.0, respectively. There was a statistically significant higher concentration of interleukin-1 receptor antagonist (IL-1Ra) in the cBMA sample (8243.3 ± 14,837.4 pg/mL) compared to both BMA (3143.0 ± 2218.5 pg/mL) and PB (1847.5 ± 1520.4 pg/mL) samples. The IL-1Ra/IL-1β ratio for PB, BMA, and cBMA was 790.6 ± 581.9, 764.7 ± 675.2, and 235.7 ± 192.1, respectively. There was no difference in the cBMA M1/M2 ratio (19.0 ± 11.1 vs 24.0 ± 18.3) between the Magellan (Isto Biologics, Hopkinton, Massachusetts) and Angel systems (Arthrex Inc, Naples, Florida).
This prospective study found that the M1/M2 ratio in cBMA was 22.1 ± 16.0, with significant patient to patient variation observed. Overall, there was no statistically significant difference in the M1/M2 ratio across PB, BMA, and cBMA samples. This is the first study to characterize the macrophage subpopulation within cBMA, which may have significant clinical implications in future studies.
本研究旨在确定接受距骨骨软骨损伤(OLTs)手术干预并使用浓缩骨髓抽吸物(cBMA)的患者中,cBMA内M1/M2巨噬细胞比例。
在手术过程中收集外周血(PB)、骨髓抽吸物(BMA)和cBMA样本。通过自动细胞计数和多色荧光激活细胞分选对样本进行分析,使用识别单核细胞(CD14+CD16+)以及该单核细胞群体内M1(CD86+)和M2(CD163+CD206+)群体的特异性抗体。用酶联免疫吸附测定(ELISA)评估样本中的细胞因子浓度。比较了两种市售BMA浓缩系统的cBMA组成。
纳入38例平均年龄为43.2±10.1岁、接受治疗OLTs的手术且使用cBMA的患者。与BMA相比,cBMA中所有白细胞平均增加4.7倍,单核细胞增加6.1倍,淋巴细胞增加7.9倍,中性粒细胞增加2.4倍,血小板增加9.6倍。PB、BMA和cBMA的平均M1/M2比值分别为15.2±12.0、20.8±13.3和22.1±16.0。与BMA样本(3143.0±2218.5 pg/mL)和PB样本(1847.5±1520.4 pg/mL)相比,cBMA样本中白细胞介素-1受体拮抗剂(IL-1Ra)浓度显著更高(8243.3±14837.4 pg/mL)。PB、BMA和cBMA的IL-1Ra/IL-1β比值分别为790.6±581.9、764.7±675.2和235.7±192.1。麦哲伦系统(Isto Biologics,马萨诸塞州霍普金顿)和安吉尔系统(Arthrex Inc,佛罗里达州那不勒斯)的cBMA M1/M2比值无差异(19.0±11.1对24.0±18.3)。
这项前瞻性研究发现cBMA中的M1/M2比值为22.1±16.0,观察到患者之间存在显著差异。总体而言,PB、BMA和cBMA样本的M1/M2比值无统计学显著差异。这是第一项对cBMA内巨噬细胞亚群进行特征描述的研究,可能对未来研究具有重要临床意义。